![](https://endpts.com/wp-content/uploads/2023/04/VintaBio-CEO-David-Radspinner.jpg)
David Radspinner, VintaBio CEO
Exclusive: Cell and gene therapy CDMO VintaBio emerges onto the scene with $64M and a new CEO
A contract manufacturer is emerging from stealth with cash on hand and a new CEO — and jumping right into the busy cell and gene therapy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.